SEARCH

SEARCH BY CITATION

References

  • 1
    Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999; 107:2S9S.
  • 2
    Heintges T, Wands JR. Hepatitis C virus: epidemiology and transmission. Hepatology 1997; 26:521526.
  • 3
    Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345:4152.
  • 4
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with Ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:14851492.
  • 5
    Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al. Randomised trial of interferon-α-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon-α-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:14261432.
  • 6
    Backmund M, Meyer K, von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34:188193.
  • 7
    Galeazzi B, Tufano A, Barbierato E, Bortolotti F. Hepatitis C virus infection in Italian intravenous drug users: epidemiological and clinical aspects. Liver 1995; 15:209212.
  • 8
    Diamantis I, Bassetti S, Erb P, Ladewig D, Gyr K, Battegay M. High prevalence and coinfection rate of hepatitis G and C infections in intravenous drug addicts. J Hepatol 1997; 26:794797.
  • 9
    Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones DB, Rustgi V, et al. Psychiatric complications of long-term interferon alpha therapy. Arch Intern Med 1987; 147:15771580.
  • 10
    Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24:778789.
  • 11
    Capuron L, Ravaud A. Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. N Engl J Med 1999; 340:1370.
  • 12
    Miyaoka H, Otsubo T, Kamijima K, Ishii M, Onuki M, Mitamura K. Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry 1999; 156:1120.
  • 13
    Shad J, Person J, Brann O, Moon S, Pockros PJ, Nyberg L, Pianco S, et al. How often are referred chronic hepatitis C patients candidates for antiviral therapy[Abstract]. Hepatology 2000; 32(Suppl):283A.
  • 14
    Taruschio G, Santarini F, Sica G, Dragoni C, Migliorini S, Andreone P, Cursaro C, et al. Psychiatric disorders in hepatitis C virus related chronic liver disease[Abstract]. Gastroenterology 1996; 110:1342A.
  • 15
    Lynch P, Peters M, Quigley M, Sreenarasaimhiah J, Cladwell C. Impact of psychiatric disorders on treatment of patients with hepatitis C[Abstract]. Gastroenterology 1998; 114(Suppl):1294A.
  • 16
    Ho SB, Nguyen H, Tetrick LL, Opitz GA, Basara ML, Dieperink E. Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population. Am J Gastroenterol 2001; 96:157164.
  • 17
    Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
  • 18
    First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV axis I disorders SCID I: clinical version 2.0. Rev. New York: Biometrics Research Department, New York State Psychiatric Institute, 1998.
  • 19
    Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339:14931499.
  • 20
    Janssen HLA, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with alpha-interferon therapy for chronic viral hepatitis. J Hepatol 1994; 21:241243.
  • 21
    Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11242 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24:3847.
  • 22
    Van Thiel DH, Friedlander L, Molloy PJ, Fagiuoli S, Kania RJ, Caraceni P. Interferon alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. Eur J Gastroent Hepatol 1995; 7:165168.
  • 23
    Pariante CM, Orru MG, Baita A, Farci MG, Carpiniello B. Treatment with interferon-α in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999; 354:131132.
  • 24
    Cantell K, Pulkkinen E, Elosuo R, Suominen J. Effect of interferon on severe psychiatric diseases. Ann Clin Res 1980; 12:131132.
  • 25
    Dobmeier M, Frick E, Frank S, Franke C, Wolfersdorf M. Schizophrenic psychosis: a contraindication for treatment of hepatitis C with interferon alpha? Pharmacopsychiatry 2000; 33:7274.
  • 26
    Cabrera-Gomez JA, Gutierrez JR, Lopez O, Gutierrez B, Garcia K, Consuegra J, Cruz R, et al. Treatment of schizophrenic disorder, paranoid type, with intramuscular recombinant alpha-2b interferon. Biotherapy 1994; 7:2737.
  • 27
    Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferon-alpha. Am J Gastroenterol 1993; 88:760761.
  • 28
    Kraus MR, Schafer A, Scheurlen M. Paroxetine for the prevention of depression induced by interferon alfa. N Engl J Med 2001; 345:375376.
  • 29
    Schaefer M, Schmidt F, Amann B, Schlosser S, Loeschke K, Grunze H. Adding low-dose antidepressants to interferon alpha treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis. Neuropsychobiology 2000; 42(Suppl 1):4345.
  • 30
    Schramm TM, Lawford BR, Macdonald GA, Cooksley WG. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust 2000; 173:359361.
  • 31
    Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 13:961966.
  • 32
    Jones TH, Wadler S, Hupart KH. Endocrine-mediated mechanisms of fatigue during treatment with interferon-α. Semin Oncol 1998; 25(Suppl I):5463.
  • 33
    Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P. Mood and cognitive side effects of interferon-α therapy. Semin Oncol 1998; 25(Suppl I):3947.
  • 34
    Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, Lo B. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001; 534:211215.
  • 35
    Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N Engl J Med 2001; 534:215216.
  • 36
    Renault PF, Hoofnagle JH. Side effects of alpha interferon. Semin Liver Dis 1989; 9:273277.